Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients - Scorecard - MDSpire

Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients

  • By

  • Carmine Valenza

  • Yue Zheng

  • Monica Milano

  • Pier Paolo Maria Berton Giachetti

  • Dario Trapani

  • Elisa Giordano

  • Lorenzo Guidi

  • Laura Boldrini

  • Grazia Castellano

  • Jalissa Katrini

  • Bianca Malagutti

  • Gabriele Antonarelli

  • Julian D. Etessami

  • Nadia Bianco

  • Fabio Conforti

  • Gregory J. Kirkner

  • Claudia Sangalli

  • Kate E. Dibble

  • Nicola Fusco

  • Marco Colleoni

  • Meredith M. Regan

  • Elisabetta Munzone

  • Giuseppe Curigliano

  • Ann H. Partridge

  • May 4, 2026

  • 0 min

Share

Clinical Scorecard: Prolonged Endocrine Treatment and Outcomes for Breast Cancer Subtypes in Premenopausal Women

At a Glance

CategoryDetail
Condition
Key MechanismsExtended endocrine therapy (EET) with LHRH agonists and oral agents reduces recurrence rates, particularly in luminal A-like subtypes.
Target Population
Care Setting

Key Highlights

  • Over 70% of patients remain recurrence-free 10 years post-5 years of LHRH agonist-based therapy (source needed).

Guideline-Based Recommendations

Diagnosis

  • Node-positive, nonmetastatic disease classified by TNM staging (ASCO and CAP guidelines).

Management

  • Consider EET for premenopausal women post-5 years of LHRH agonist therapy (specific criteria needed).

Monitoring & Follow-up

    Risks

      Patient & Prescribing Data

      EET options include tamoxifen monotherapy or LHRH agonist combined with tamoxifen or aromatase inhibitors, based on individual risk factors.

      Clinical Best Practices

      • Monitor for adverse effects of prolonged endocrine therapy, including vasomotor symptoms and psychosocial impacts.

      References

      Original Source(s)

      Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients

      • by Carmine Valenza, Yue Zheng, Monica Milano, Pier Paolo Maria Berton Giachetti, Dario Trapani, Elisa Giordano, Lorenzo Guidi, Laura Boldrini, Grazia Castellano, Jalissa Katrini, Bianca Malagutti, Gabriele Antonarelli, Julian D. Etessami, Nadia Bianco, Fabio Conforti, Gregory J. Kirkner, Claudia Sangalli, Kate E. Dibble, Nicola Fusco, Marco Colleoni, Meredith M. Regan, Elisabetta Munzone, Giuseppe Curigliano, Ann H. Partridge

      • May 4, 2026

      Related Content

      Effects of SOX10 on the proliferative, invasive, migratory, and epithelial–mesenchymal transition abilities of triple-negative breast cancer cells

      HiGATE: hierarchical graph attention for multi-scale tissue encoder in computational pathology

      Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC